Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

Insight Into Genomic Correlates of PD-L1 Expression and the Response to Immune Checkpoint Blockade

Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

Letter to the Editor: Previously Excluded Patients with Autoimmune Disorders, HIV, and More

PACIFIC Flooded Us with Optimism. Now What?

Bringing Lung Cancer Screening into Communities: An NHS Pilot Program’s Success

Uncommon Oncogenic Drivers in NSCLC

IMpower133: Finally Moving the Needle in SCLC

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status